What it is claimed to help
These are the uses attached to LL-37 in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.
What the human evidence actually is
Small, uncontrolled, foreign-registry or single-group human studies only.
Limited but real. A randomised phase 2b in Sweden tested LL-37 on hard-to-heal venous leg ulcers and reported improved healing at low doses. That is one small trial, not a body of evidence. Note the paradox: LL-37 is over-expressed in rosacea lesions, so more is not automatically better.
How it is supposed to work
Cationic amphipathic peptide that disrupts bacterial membranes and modulates host immune signalling and angiogenesis.
Safety
Cytotoxic at higher concentrations; dose-dependence cut both ways in the ulcer trial. Systemic use is not characterised.
Storage and handling
Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.
Whatever number a protocol or a prescriber gave you, converting it into syringe units is where a misplaced decimal becomes a tenfold error. Our calculators do that conversion and nothing else — they never invent a dose.
Open the calculatorsSources
- Grönberg A et al. LL-37 in venous leg ulcers, Wound Repair Regen 2014
- FDA PCAC scheduling notice, April 2026
Verified against primary sources on 27 August 2026. Regulatory status in this field changes several times a year. See How We Rate Evidence.